Preventive

Preventive is a public benefit corporation (PBC) conducting research into preventing genetic diseases before birth. The company's primary mission is to explore whether new gene-editing technologies, like CRISPR, can be used safely and responsibly to correct severe genetic conditions for future generations. Their stated goal is to determine through rigorous preclinical research if preventive gene editing can be developed safely to spare families from severe diseases. The company has affirmed that it will not proceed with clinical human use if safety cannot be thoroughly established and will not compromise safety standards to speed up timelines.

The company was announced in October 2025 by co-founder Lucas Harrington, who received his Ph.D. in the lab of CRISPR Nobel Laureate Jennifer Doudna and also co-founded Mammoth Biosciences. Other team members include Matt Krisiloff, CEO of Conception Biosciences; Peyton Randolph, a co-inventor of prime editing; and Dr. Paula Amato, former President of the American Society for Reproductive Medicine. Preventive has raised nearly $30 million from private funders to support its research.

Preventive operates in the biotechnology and genetic research market, focusing on a controversial area of science. The company's business is centered on research and development, with the potential future commercialization of gene-editing therapies if they are proven safe and effective. This approach aims to address the root genetic cause of diseases before symptoms emerge, a shift from managing symptoms after a disease has already developed.

Keywords: gene editing, CRISPR, preventive medicine, genetic disease, preclinical research, biotechnology, reproductive technology, prime editing, public benefit corporation, inherited disease, genetic conditions, conception biosciences, genetic research, molecular biology, therapeutics